Changes in survival rate of multiple myeloma after the introduction of bortezomib: a single institutional experience over 20 years

A new staging system to predict prognosis of patients with multiple myeloma in an era of novel therapeutic agents

(2014) Hirono Iriuchishima et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Autologous stem cell transplantation for elderly patients with newly diagnosed multiple myeloma in the era of novel agents

(2013) M. Merz et al.   ANNALS OF ONCOLOGY

Chromosomal Abnormalities Are Major Prognostic Factors in Elderly Patients With Multiple Myeloma: The Intergroupe Francophone du Myélome Experience

(2013) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiple Myeloma Treatment Transformed: A Population-Based Study of Changes in Initial Management Approaches in the United States

(2013) Joan L. Warren et al.   JOURNAL OF CLINICAL ONCOLOGY

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

(2013) S K Kumar et al.   LEUKEMIA

Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics

(2012) Y Kanda   BONE MARROW TRANSPLANTATION

Multiple myeloma in octogenarians: Clinical features and outcome in the novel agent era

(2012) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

(2011) A. Palumbo et al.   BLOOD

Light Chain–Induced Acute Renal Failure Can Be Reversed by Bortezomib-Doxorubicin-Dexamethasone in Multiple Myeloma: Results of a Phase II Study

(2010) Heinz Ludwig et al.   JOURNAL OF CLINICAL ONCOLOGY

Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based Study

(2009) Ingemar Turesson et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)

(2009) E Kastritis et al.   LEUKEMIA

VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma

(2008) M Pineda-Roman et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE